Literature DB >> 35508109

Microbiota alterations in proline metabolism impact depression.

Jordi Mayneris-Perxachs1, Anna Castells-Nobau2, María Arnoriaga-Rodríguez3, Miquel Martin4, Lisset de la Vega-Correa2, Cristina Zapata2, Aurelijus Burokas5, Gerard Blasco6, Clàudia Coll7, Anira Escrichs8, Carles Biarnés9, José María Moreno-Navarrete3, Josep Puig10, Josep Garre-Olmo11, Rafel Ramos12, Salvador Pedraza13, Ramón Brugada14, Joan Carles Vilanova15, Joaquín Serena16, Jordi Gich17, Lluís Ramió-Torrentà18, Vicente Pérez-Brocal19, Andrés Moya20, Reinald Pamplona21, Joaquim Sol22, Mariona Jové21, Wifredo Ricart3, Manuel Portero-Otin21, Gustavo Deco23, Rafael Maldonado24, José Manuel Fernández-Real25.   

Abstract

The microbiota-gut-brain axis has emerged as a novel target in depression, a disorder with low treatment efficacy. However, the field is dominated by underpowered studies focusing on major depression not addressing microbiome functionality, compositional nature, or confounding factors. We applied a multi-omics approach combining pre-clinical models with three human cohorts including patients with mild depression. Microbial functions and metabolites converging onto glutamate/GABA metabolism, particularly proline, were linked to depression. High proline consumption was the dietary factor with the strongest impact on depression. Whole-brain dynamics revealed rich club network disruptions associated with depression and circulating proline. Proline supplementation in mice exacerbated depression along with microbial translocation. Human microbiota transplantation induced an emotionally impaired phenotype in mice and alterations in GABA-, proline-, and extracellular matrix-related prefrontal cortex genes. RNAi-mediated knockdown of proline and GABA transporters in Drosophila and mono-association with L. plantarum, a high GABA producer, conferred protection against depression-like states. Targeting the microbiome and dietary proline may open new windows for efficient depression treatment.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amino acids; brain; cognition; depression; diet; gut microbiota; proline

Mesh:

Substances:

Year:  2022        PMID: 35508109     DOI: 10.1016/j.cmet.2022.04.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   31.373


  6 in total

Review 1.  The enigma of vascular depression in old age: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-15       Impact factor: 3.850

Review 2.  Gut Microbiome: A Brief Review on Its Role in Schizophrenia and First Episode of Psychosis.

Authors:  Konstantinos Tsamakis; Sofia Galinaki; Evangelos Alevyzakis; Ioannis Hortis; Dimitrios Tsiptsios; Evangelia Kollintza; Stylianos Kympouropoulos; Konstantinos Triantafyllou; Nikolaos Smyrnis; Emmanouil Rizos
Journal:  Microorganisms       Date:  2022-05-29

3.  Trimethylamine N-Oxide Reduces the Susceptibility of Escherichia coli to Multiple Antibiotics.

Authors:  Jiaxin Qiao; Yan Liang; Yao Wang
Journal:  Front Microbiol       Date:  2022-07-07       Impact factor: 6.064

4.  Antidepressant-like activity, active components and related mechanism of Hemerocallis citrina Baroni extracts.

Authors:  Jinghong Liu; Tian Ye; Shuaiyong Yang; Xiaohong Zhong; Wei He; Mengtao Xu; Jinpeng Fang; Miao Deng; Ning Xu; Jianguo Zeng; Zhixing Qing
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

5.  Whole-brain dynamics differentiate among cisgender and transgender individuals.

Authors:  Carme Uribe; Anira Escrichs; Eleonora de Filippi; Yonatan Sanz-Perl; Carme Junque; Esther Gomez-Gil; Morten L Kringelbach; Antonio Guillamon; Gustavo Deco
Journal:  Hum Brain Mapp       Date:  2022-05-18       Impact factor: 5.399

6.  Neferine alleviates chronic stress-induced depression by regulating monoamine neurotransmitter secretion and gut microbiota structure.

Authors:  Zaiquan Dong; Qinglian Xie; Feiyu Xu; Xiaoling Shen; Yanni Hao; Jin Li; Haizhen Xu; Qiang Peng; Weihong Kuang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.